Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock Holdings Decreased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 22.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 71,464 shares of the life sciences company’s stock after selling 21,053 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.09% of Integra LifeSciences worth $1,621,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IART. Sachem Head Capital Management LP acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at about $44,153,000. Dimensional Fund Advisors LP increased its stake in Integra LifeSciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after buying an additional 12,766 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after buying an additional 125,620 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Integra LifeSciences by 64.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after buying an additional 335,557 shares during the period. Finally, Glenmede Trust Co. NA grew its holdings in shares of Integra LifeSciences by 125.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock valued at $13,224,000 after acquiring an additional 405,624 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Up 3.0 %

Shares of IART opened at $25.60 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The company has a 50-day moving average price of $23.26 and a two-hundred day moving average price of $22.39. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -284.41, a P/E/G ratio of 0.84 and a beta of 1.16. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period in the previous year, the business earned $0.76 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. Equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IART shares. Citigroup raised their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Truist Financial cut their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.